文献速递冠心病心力衰竭与心肌病

心肌梗死后左室射血分数全谱系的心脏性猝死风险:一项荟萃分析

Sudden cardiac death risk after myocardial infarction across the spectrum of left ventricular ejection fraction: a meta-analysis.
PubMed 文献 · Heart · 2026-08-03

该荟萃分析纳入5项研究共9345例心肌梗死后患者,评估左室射血分数(LVEF)36-50%患者的心脏性猝死(SCD)负担。结果显示该人群SCD年发生率为1.74%(95%CI 1.02-2.95),高于LVEF>50%的0.55%(p=0.02),低于LVEF≤35%的6.34%(p=0.03);探索性模型显示一级预防ICD的需治疗人数为19。

要点

  • LVEF 36-50%心梗后患者SCD年发生率为1.74%,存在临床相关未满足需求。
  • LVEF≤35%患者SCD年发生率6.34%,显著高于LVEF 36-50%人群(p=0.03)。
  • 探索性模型显示该人群一级预防ICD的5年NNT为19。

核心结论

  • 心肌梗死后LVEF 36-50%患者虽不符合现行ICD适应证,但仍承载显著的SCD负担。
  • 需进一步研究优化该人群风险分层并确定合适干预是否获益。

研究设计与样本

  • 系统综述与荟萃分析,检索Medline、Embase和Cochrane数据库从建库至当前。
  • 纳入报告LVEF 36-50%心梗后患者死亡和SCD结局且无额外风险分层或干预的研究。
  • 共识别7435条记录,最终纳入5项研究、9345例患者。
  • 采用随机效应模型合成数据,并计算竞争风险校正的ICD植入NNT。

主要发现

  • LVEF 36-50%心梗后患者汇总SCD年发生率为1.74%(95%CI 1.02-2.95)。
  • LVEF≤35%患者SCD年发生率为6.34%,显著高于LVEF 36-50%人群(p=0.03)。
  • LVEF>50%患者SCD年发生率为0.55%,显著低于LVEF 36-50%人群(p=0.02)。
  • SCD占总死亡的比例在各LVEF分层间相似(p=0.79)。
  • 研究间异质性很高(SCD的I2=89.9%,全因死亡的I2=96.8%)。

关键数值与推荐

  • 探索性建模中,应用MADIT-II的ICD治疗效应(HR 0.33,95%CI 0.20-0.53)并外推至5年设备寿命时,LVEF 36-50%患者一级预防ICD的NNT为19。

临床怎么用

  • 提示临床对心梗后LVEF 36-50%患者应关注SCD风险,现行ICD适应证可能未覆盖该人群。
  • 该人群ICD获益的探索性NNT数据可供医患沟通参考,但需进一步研究验证。

局限性

  • 纳入研究间异质性很高(SCD的I2=89.9%,全因死亡的I2=96.8%)。
  • 仅纳入5项研究,样本量有限。
  • ICD的NNT来自探索性建模和外推,非直接随机对照证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Implantable cardioverter defibrillator (ICD) therapy is indicated following a myocardial infarction (MI) to curtail the risk of sudden cardiac death (SCD) in patients who are classified as high-risk, defined by a left ventricular ejection fraction (LVEF) ≤35%. The understanding of risk in patients with ischaemic injury who do not meet these criteria is limited. This study aims to assess the burden of SCD in patients' post-MI with LVEF 36-50%. METHODS: Articles reporting mortality and SCD outcomes for participants with LVEF 36-50% post-MI without additional risk stratification or intervention were included. Medline, Embase and Cochrane databases were searched from index entries until the present. Data were synthesised using a random-effects model. Competing risk adjusted number needed to treat (NNT) for ICD implantation was calculated. This study adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. RESULTS: 7435 records were identified, five studies with 9345 patients were included. The pooled annual rate of SCD in patients with LVEF 36-50% post-MI was 1.74% (95% CI 1.02 to 2.95); a higher annual rate of 6.34% was observed for LVEF≤35% (p=0.03) while a lower yearly rate of 0.55% was observed for LVEF >50% (p=0.02). The proportion of mortality due to SCD was similar across all LVEF strata (p=0.79). Very high between-study heterogeneity was observed (I2=89.9% for SCD and I2=96.8% for all-cause mortality). During exploratory modelling, the primary prevention ICD NNT for patients with LVEF 36-50% was 19 when applying the MADIT-II ICD treatment effect (HR 0.33, 95% CI 0.20 to 0.53) and extrapolation to a 5-year device lifespan. CONCLUSION: This is the first meta-analysis reviewing post-MI patients with LVEF 36-50%. These findings highlight a clinically relevant unmet need for patients who carry a substantial burden of SCD despite being outside current ICD eligibility criteria. Further study is needed to improve risk stratification within this population and determine whether suitable intervention is beneficial. PROSPERO REGISTRATION NUMBER: CRD42024551830.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Lau, Abotabekh, Liu, et al. Sudden cardiac death risk after myocardial infarction across the spectrum of left ventricular ejection fraction: a meta-analysis. Heart. 2026. PMID: 42571650. doi:10.1136/heartjnl-2026-327792

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。